Allogeneic Gamma-delta T Cells Combined With Targeted Therapy and Immunotherapy in a Phase 1 Clinical Trial of Hepatocellular Carcinoma Resistant to PD-1 Monoclonal Antibody - Trial NCT06364800
Access comprehensive clinical trial information for NCT06364800 through Pure Global AI's free database. This Phase 1 trial is sponsored by Beijing 302 Hospital and is currently Not yet recruiting. The study focuses on Hepatocellular Carcinoma. Target enrollment is 18 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Beijing 302 Hospital
Timeline & Enrollment
Phase 1
Apr 26, 2024
Sep 26, 2026
Primary Outcome
Safety evaluation: Incidence of Adverse events (AEs),Safety evaluation: Dose limited toxicity (DLTs),Efficacy evaluation: Objective Response Rate(ORR),Efficacy evaluation: Duration of Response(DOR),Efficacy evaluation: Progress Free Survival(PFS),Efficacy evaluation: Overall Survival (OS)
Summary
The purpose of this study is to evaluate the safety and efficacy of allogeneic ฮณฮด T cells
 combined with targeted therapy and PD-1 monoclonal antibody in patients with hepatocellular
 carcinoma resistant to PD-1 monoclonal antibody.
 
 Hepatocellular Carcinoma
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06364800
Non-Device Trial